With the Biden administration’s recent announcement of the first 10 drugs to be negotiated for Medicare as part of the Inflation Reduction Act (IRA), an array of legal challenges from the pharmaceutical industry is potentially the biggest obstacle to implementation. In court filings, individual drugmakers and the industry’s main lobbying group contend that the negotiations<span class="readmore-ellipsis">…</span><a href="https://www.kff.org/medicare/event/sept-12-probing-the-legal-arguments-in-the-drug-industrys-challenges-to-medicare-drug-price-negotiations/" class="see-more light-beige no-float inline-readmore">More</a></p>
The Centers for Medicare and Medicaid Services on Tuesday announced the first 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act, a critical